Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹1,786 Cr
verified against source
Revenue YoY
8.7%
reported change
EBITDA
₹380 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Fortis Healthcare reported a strong Q4 FY24 with consolidated revenue of ₹1,786 crore (+8.7% YoY) and EBITDA margin of 21.3% (+480bps YoY), driven by hospital business margin expansion to 22.4% (adjusted ~21%). PAT grew 46.9% to ₹203 crore. Hospital revenue grew 10.3% YoY, supported by ARPOB growth of 10.8% (3% price, rest mix) and higher surgical volumes. Diagnostics revenue was soft (+2%) due to rebranding and one-offs, but non-COVID revenue grew 5%. Management guided for ~200bps YoY EBITDA margin improvement in FY25, with brownfield bed additions of ~700 beds (including Manesar) and a target of 6,000 beds over next few years. Key risks include potential dilution from Agilus put option exercise (~₹1,200-1,300 crore) and ongoing legal cases (₹30-50 crore annual cost).
Colored figures show movement against the previous available record.
Guidance to track
- Hospital operating EBITDA margin expected to improve by ~200bps in FY25, building on FY24's 18.6% (hospital) and 18.4% consolidated.
- Includes 50 beds each at Faridabad and Kalyan, 100 beds at Manesar (Q2), 100 beds at Kolkata (Q1), and beds at BG Road (Q2).
- ARPOB growth expected to moderate to 4-5% in medium term from 10.8% in FY24, driven by 2-2.5% price increases and case mix improvement.
- Management expects to finalize the put option (due Oct 2024) by August-September 2024, with options including IPO revival or buyout via debt/equity.
Risks flagged
- If PE investor exercises put option, Fortis may need to raise ~₹1,200-1,300 crore, potentially via debt or equity, impacting leverage or dilution.
- Annual legal costs of ₹30-50 crore related to legacy issues (brand, forensic audit) may persist until resolution; Supreme Court stay on promoter shareholding dismissed.
- Agilus volumes grew only 0.6% in Q4 despite rebranding; competitive pressures and government business provisions may delay margin recovery.
- Government revenue (20% of hospital) may benefit from CGHS rate revision, but timing and quantum are uncertain; not factored into guidance.
Key quotes
- We are maintaining our guidance which we have given earlier. We could demonstrate around 2% EBITDA margin improvement over the last year. I am expecting similar type of slightly better than this in the next financial year.
- We are working with the private equity investor to come out with a solution for this particular thing. So, one option is for the revival of the IPO, so that we are working with bankers along with the private equity investors for revival of the IPO.
- The healthcare industry remains so much under the glare of media and public interest groups, that the industry has to calibrate the price changes very, very carefully.
Research modules